Spero Therapeutics(SPRO) - 2024 Q3 - Quarterly Results

Financial Position - Estimated cash and cash equivalents of approximately $76.3 million as of September 30, 2024[2] - Existing cash and cash equivalents expected to fund operating expenses and capital expenditures into mid-2026[5] Workforce and Restructuring - Company announced a workforce reduction of approximately 39$1.1 million related to severance pay and termination benefits[5] - Company may incur additional costs related to the workforce reduction not currently contemplated[5] Business Operations and Strategy - Company released an investor presentation providing updates on business and operations[6] - Company emphasizes reliance on third parties for manufacturing and commercialization of product candidates[11] Forward-Looking Statements - Forward-looking statements indicate potential regulatory delays and the need for additional funding[9] - Anticipated expenses and cash runway are subject to various important factors that may affect actual results[9] - Completion of quarterly results will be included in the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2024[3]